Stay updated on Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Plain Language Summary and data-sharing links (Trialstransparency PDF, externaldatasharing-msd). Removed older EngageZone data-sharing documents and updated revision to v3.4.2.SummaryDifference0.2%

- Check21 days agoChange DetectedAdded Revision: v3.4.1 and removed Revision: v3.4.0; this appears to be revision metadata only. No study content such as eligibility criteria, locations, or outcomes has changed.SummaryDifference0.0%

- Check28 days agoChange DetectedAdded: Show glossary, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0. Removed: Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page shows a minor revision update from v3.3.3 to v3.3.4; no content changes to the study details or documents are apparent. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedLocations have been added and updated across numerous regions worldwide, expanding the list of study sites. This expands enrollment access by giving participants more nearby sites and clearer site information.SummaryDifference4%

- Check92 days agoChange DetectedAdded a new publication citation for LEAP-003 results (Ann Oncol. 2025) in Publications and updated the existing entry to Revision: v3.3.2 (from v3.2.0).SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.